Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Occupational Exposure Concerns

The legacy context of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad framework, discussions of pharmaceutical interventions have historically emphasized their intended effects while acknowledging potential adverse outcomes. This heritage of balanced health communication provides a natural starting point for examining specific drug-safety questions that arise in both clinical and occupational settings. As we pivot from this general health perspective toward a more focused concern, the transition involves recognizing how certain medications, originally developed for widespread therapeutic use, may present distinct risks in particular exposure scenarios. The query regarding Fosamax and its potential association with osteonecrosis of the jaw exemplifies this shift. While the general health context might address this as a rare adverse event in patient populations, the occupational exposure concern reframes the issue: workers involved in the manufacturing, handling, or disposal of such bisphosphonate compounds may face unique exposure pathways that differ from prescribed patient use. This pivot does not require mechanistic claims about disease causation. Instead, it simply acknowledges that the same substance, when encountered occupationally—through inhalation, dermal contact, or accidental ingestion—could pose risks that warrant separate consideration from the therapeutic context. The bridge concept thus moves from general health awareness to a precautionary occupational perspective, setting the stage for a more targeted examination of exposure scenarios without presupposing any specific causal relationship.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but more commonly associated with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation typically involves pain, swelling, and exposed bone in the jaw, which can lead to significant morbidity. Diagnosis relies on clinical examination and imaging, with a multiscale characterization of jawbone providing insights into bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression may impair the jawbone's ability to repair microdamage and respond to local infections or trauma, particularly in areas with high bone remodeling, such as the mandible and maxilla. The jawbone's unique structure and vascular supply may make it more susceptible to these effects (https://pubmed.ncbi.nlm.nih.gov/40345077/). Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Evidence for Causation and Clinical Management

Regarding causation, the time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event that may not be solely attributable to the drug in all cases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, discontinuation of Fosamax often leads to relief of symptoms, and a subset of patients experienced recurrence when rechallenged with the same drug or another bisphosphonate, supporting a causal relationship (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions,' detailing the association, risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This information is intended to inform healthcare providers and patients of the potential risk, though the rarity of ONJ may limit its detection in clinical trials. For affected patients, causation considerations include the presence of other risk factors, such as dental procedures or concomitant medications, which may contribute to the development of ONJ. The timeline between exposure and documented harm can be variable, with symptoms appearing as early as one day or after several months of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In cases where ONJ occurs, management typically involves discontinuation of the bisphosphonate, conservative dental care, and addressing any underlying infections or contributing factors. In summary, while Fosamax is effective for osteoporosis and other bone conditions, it is associated with a risk of ONJ, particularly in patients with additional risk factors. The evidence supports a causal link, as demonstrated by symptom relief upon discontinuation and recurrence upon rechallenge, though the overall incidence is low. Clinicians should weigh the benefits of Fosamax against the potential for ONJ, especially in patients undergoing invasive dental procedures or with other predisposing conditions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence that Fosamax causes osteonecrosis of the jaw?

Evidence includes symptom relief upon discontinuation and recurrence upon rechallenge with Fosamax or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in clinical trials, the incidence of ONJ symptoms was similar between Fosamax and placebo groups, indicating it is a rare event.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use also increases risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.